Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cordis Looks To Regain Previous Innovation Edge With Drug-Eluting Balloons

Executive Summary

Medtech Insight followed-up with Cordis CEO Shar Matin to talk about the company’s path forward as an innovative intervention company following the acquisition of MedAlliance.

You may also be interested in...



Cardinal Agrees To Sell Cordis For $1Bn To Hellman & Friedman

Cardinal said it remains “committed to its medical distribution and global medical products businesses” despite the divesture of Cordis.

INTERVIEW: The bigger value picture behind Cardinal Health's Cordis buy

When Johnson & Johnson agreed to sell Cordis to Cardinal Health for nearly $2bn last month, many saw Cardinal Health taking on a portfolio of mature medical devices – albeit of a well-established and globally recognized brand – that did not offer that much differentiation from the competition. So what’s in it for Cardinal Health and what’s the overriding objective behind the move? Tina Tan speaks to Don Casey, CEO of Cardinal Health’s Medical Segment, who spent nearly 26 years at J&J, to find out more about the underlying market changes and the strategy that motivated the company to make not only this particular acquisition, but likely more similar deals in the future

Minute Insight: Abbott Rolls Out Navitor Next-Gen TAVR System To Catch Up To Medtronic And Edwards

Navitor is an upgraded version of Abbott’s Portico TAVR system with a better fabric cuff and large curved aortic “cells” to reduce the risk of injury to the native valve.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147377

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel